WO2007115805A3 - Aurora kinase inhibitors - Google Patents

Aurora kinase inhibitors Download PDF

Info

Publication number
WO2007115805A3
WO2007115805A3 PCT/EP2007/003136 EP2007003136W WO2007115805A3 WO 2007115805 A3 WO2007115805 A3 WO 2007115805A3 EP 2007003136 W EP2007003136 W EP 2007003136W WO 2007115805 A3 WO2007115805 A3 WO 2007115805A3
Authority
WO
WIPO (PCT)
Prior art keywords
aurora kinase
kinase inhibitors
kinase activity
compounds
ameliorating
Prior art date
Application number
PCT/EP2007/003136
Other languages
French (fr)
Other versions
WO2007115805A2 (en
Inventor
Joe Lewis
Original Assignee
European Molecular Biology Lab Embl
Joe Lewis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by European Molecular Biology Lab Embl, Joe Lewis filed Critical European Molecular Biology Lab Embl
Publication of WO2007115805A2 publication Critical patent/WO2007115805A2/en
Publication of WO2007115805A3 publication Critical patent/WO2007115805A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides novel compounds that inhibit cell proliferation, in particular by inhibiting Aurora kinase activity and uses of these compounds for treating, ameliorating or preventing diseases, conditions or disorders benefiting from the inhibition of Aurora kinase activity, in particular hyperproliferative diseases.
PCT/EP2007/003136 2006-04-05 2007-04-05 Aurora kinase inhibitors WO2007115805A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EPPCT/EP2006/003111 2006-04-05
EP2006003111 2006-04-05

Publications (2)

Publication Number Publication Date
WO2007115805A2 WO2007115805A2 (en) 2007-10-18
WO2007115805A3 true WO2007115805A3 (en) 2008-06-05

Family

ID=36636565

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/003136 WO2007115805A2 (en) 2006-04-05 2007-04-05 Aurora kinase inhibitors

Country Status (1)

Country Link
WO (1) WO2007115805A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
PT3289876T (en) 2008-06-16 2022-10-28 Univ Tennessee Res Found Compounds for treatment of cancer
MX2011003151A (en) 2008-10-01 2011-04-27 Bayer Cropscience Ag Heterocyclyl-substituted thiazoles as plant protection agents.
ES2422718T3 (en) 2009-04-02 2013-09-13 Merck Patent Gmbh Piperidine and piperazine derivatives as autotaxin inhibitors
RU2581367C2 (en) 2010-03-01 2016-04-20 Джи Ти Икс, ИНК. Compounds for treating cancer
LT2850075T (en) * 2012-04-25 2017-05-10 Theravance Biopharma R&D Ip, Llc Piperazine-piperidine compounds as hepatitis c virus inhibitors
WO2015005305A1 (en) * 2013-07-09 2015-01-15 小野薬品工業株式会社 Alxr agonist compound
AU2014318821B2 (en) * 2013-09-10 2018-04-19 Board Of Regents Of The University Of Texas System Therapeutics targeting truncated Adenomatous Polyposis Coli (APC) proteins

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026923A1 (en) * 1995-03-02 1996-09-06 Pierre Fabre Medicament Novel bi-tryptaminic derivatives, preparation process and utilization as drugs
EP1057815A1 (en) * 1998-02-19 2000-12-06 Kowa Co., Ltd. Cyclic amide compounds
US6344449B1 (en) * 1996-09-10 2002-02-05 Dr. Karl Thomae Gmbh Modified aminoacids, pharmaceuticals containing these compounds and method for their production
WO2003097855A2 (en) * 2002-05-14 2003-11-27 Baylor College Of Medicine Small molecule inhibitors of her2 expression
WO2003103671A1 (en) * 2002-06-07 2003-12-18 Menarini Ricerche S.P.A. Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom
FR2856685A1 (en) * 2003-06-25 2004-12-31 Merck Sante Sas THIAZOLYLPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2005116653A2 (en) * 2004-04-13 2005-12-08 Arena Pharmaceuticals, Inc. Modulators of human g protein-coupled receptors for the treatment of hyperglycemia and related disorders
EP1637529A1 (en) * 2004-09-20 2006-03-22 4Sc Ag Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof
EP1832586A1 (en) * 2006-03-10 2007-09-12 Oridis Biomed Forschungs- und Entwicklungs GmbH Thiazole-piperidine derivatives in treatment of diseases of liver and the pancreas
WO2007104557A2 (en) * 2006-03-15 2007-09-20 4Sc Ag Novel heterocyclic nf-kb inhibitors
WO2007104558A1 (en) * 2006-03-15 2007-09-20 4Sc Ag Thiazoles as nf-kb inhibitors (proteasome inhibitors)

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026923A1 (en) * 1995-03-02 1996-09-06 Pierre Fabre Medicament Novel bi-tryptaminic derivatives, preparation process and utilization as drugs
US6344449B1 (en) * 1996-09-10 2002-02-05 Dr. Karl Thomae Gmbh Modified aminoacids, pharmaceuticals containing these compounds and method for their production
EP1057815A1 (en) * 1998-02-19 2000-12-06 Kowa Co., Ltd. Cyclic amide compounds
WO2003097855A2 (en) * 2002-05-14 2003-11-27 Baylor College Of Medicine Small molecule inhibitors of her2 expression
WO2003103671A1 (en) * 2002-06-07 2003-12-18 Menarini Ricerche S.P.A. Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom
FR2856685A1 (en) * 2003-06-25 2004-12-31 Merck Sante Sas THIAZOLYLPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2005116653A2 (en) * 2004-04-13 2005-12-08 Arena Pharmaceuticals, Inc. Modulators of human g protein-coupled receptors for the treatment of hyperglycemia and related disorders
EP1637529A1 (en) * 2004-09-20 2006-03-22 4Sc Ag Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof
US20060069102A1 (en) * 2004-09-20 2006-03-30 4 Sc Ag Novel heterocyclic NF-kB inhibitors
EP1832586A1 (en) * 2006-03-10 2007-09-12 Oridis Biomed Forschungs- und Entwicklungs GmbH Thiazole-piperidine derivatives in treatment of diseases of liver and the pancreas
WO2007104557A2 (en) * 2006-03-15 2007-09-20 4Sc Ag Novel heterocyclic nf-kb inhibitors
WO2007104558A1 (en) * 2006-03-15 2007-09-20 4Sc Ag Thiazoles as nf-kb inhibitors (proteasome inhibitors)

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
KING HAROLD ET AL: "Antiplasmodial action and chemical constitution. III. Carbinolamines derivedfrom naphthalene and quinoline", JOURNAL OF THE CHEMICAL SOCIETY, CHEMICAL SOCIETY. LETCHWORTH, GB, 1940, pages 1307 - 1315, XP008090078, ISSN: 0368-1769 *
NIELSEN, ARNOLD T. ET AL: "1,1'-Diacetyl-1,1'-dihydro-4,4'-bipyridine and the yellow and colorless modifications of 1,1'-diacetyl-1,1' ,4,4'-tetrahydro-4,4'-bipyridine. The 1,1'-diacetyl-4,4'-bipyridine radical cation", JOURNAL OF ORGANIC CHEMISTRY , 29(8), 2175-9 CODEN: JOCEAH; ISSN: 0022-3263, 1964, XP002476438 *
PIATTI, S. E. ET AL: "Synthesis of bisquinoxaline derivatives with potential neoplastic activity", ANALES DE QUIMICA, SERIE C: QUIMICA ORGANICA Y BIOQUIMICA , 82(2), 85-8 CODEN: AQSBD6; ISSN: 0211-1357, 1986, XP008090352 *
SHIMOGAWA, HIROKI ET AL: "A Wrench-Shaped Synthetic Molecule that Modulates a Transcription Factor-Coactivator Interaction", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY , 126(11), 3461-3471 CODEN: JACSAT; ISSN: 0002-7863, 2004, XP002476439 *
TUMIATTI, VINCENZO ET AL: "Structure-Activity Relationships of Acetylcholinesterase Noncovalent Inhibitors Based on a Polyamine Backbone. 3. Effect of Replacing the Inner Polymethylene Chain with Cyclic Moieties", JOURNAL OF MEDICINAL CHEMISTRY , 47(26), 6490-6498 CODEN: JMCMAR; ISSN: 0022-2623, 2004, XP002476440 *

Also Published As

Publication number Publication date
WO2007115805A2 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
WO2007115805A3 (en) Aurora kinase inhibitors
WO2005111039A3 (en) Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
WO2007123892A3 (en) Raf inhibitors and their uses
WO2007098507A3 (en) Compositions and methods for inhibition of the jak pathway
WO2008011560A3 (en) Benzothiophene inhibitors of rho kinase
WO2008094737A3 (en) Purine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases
WO2008021038A3 (en) Pyridobenzazepine compounds and methods for inhibiting mitotic progression
WO2007021941A3 (en) Inhibitors of voltage-gated sodium channels
WO2006071960A3 (en) Compositions and methods of treating cell proliferation disorders
WO2007019251A3 (en) Sphingosine kinase inhibitors and methods of their use
WO2006133426A3 (en) Compositions and methods for inhibition of the jak pathway
WO2007059230A3 (en) Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
WO2006091395A3 (en) Inhibitors of akt activity
WO2007104053A3 (en) 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
WO2006135627A3 (en) Inhibitors of akt activity
WO2008070041A3 (en) Inhibitors of akt activity
WO2008131000A3 (en) 7-substituted indole mcl-1 inhibitors
WO2007079164A3 (en) Protein kinase inhibitors
WO2007095124A3 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
WO2008049123A8 (en) 2,4-pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases
WO2007087245A3 (en) Ret tyrosine kinase inhibition
WO2009129335A3 (en) Selective inhibitors of histone deacetylase
MX2009006535A (en) Indol-4-yl-pyrimidinyl-2-yl-amine derivatives and use thereof as cyclin dependant kinase inhibitors.
MY153243A (en) Compound for inhibiting mitotic progression
WO2006110638A3 (en) Inhibitors of akt activity

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07724077

Country of ref document: EP

Kind code of ref document: A2